Skip to main content

Evaluation of tacrine hydrochloride (Cognex®) in two parallel‐group studies

Buy Article:

$51.00 plus tax (Refund Policy)


The efficacy of tacrine hydrochloride (Cognex®) for the treatment of Alzheimer's disease (AD) has been confirmed in two randomized, double‐blind, placebo‐controlled, parallel‐group studies. More than 1100 patients with mild to moderate, probable AD were randomized to receive placebo or tacrine for 12 or 30 weeks. Outcome measures included objective assessments of cognitive function, qualitative assessments of treatment response from the caregiver and clinician perspective, and assessments of activities of daily living. Statistically significant treatment effects favoring tacrine were demonstrated in each domain. These results suggest several considerations for clinicians. Because response to treatment is dose related, patients should be titrated to their maximum tolerated dose. Response may be subtle and may range from improvement to stabilization or slowed decline. A minimum treatment period of 6 months is recommended to evaluate a response and treatment should be continued depending on patient tolerability.

Document Type: Original Article


Affiliations: CNS Clinical Department, Parke-Davis, Ann Arbor, MI, USA

Publication date: 1996-04-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more